Veterinary Health Products, commonly referred to as VHPs, are regulated in Canada as low-risk drugs under the Food and Drugs Act and the Food and Drug Regulations. Within this framework, VHPs are finished, ready to use products sold in a “dose” format, such as tablets, capsules, liquids, powders, pastes, chews, sprays, or topical preparations, Bulk ingredients or feed materials are not considered VHPs and are governed separately.
Any VHP that is manufactured, imported, or sold in Canada is subject to mandatory notification to Health Canada at least 30 calendar days before sale in Canada, and before importation, in accordance with the Food and Drug Regulations and the VHP Notification Program guidance.
This guide provides a practical overview of the key steps VHP brands must follow to successfully notify their products in Canada, along with the post-market obligations that support ongoing product control and safety assurance. Please note, this article is intended for general informational purposes only and should not be relied upon as a substitute for legal advice or professional regulatory guidance. For tailored, product-specific support, the SNI regulatory team is available to provide expert assistance with VHP notifications, labelling, and end-to-end compliance for the Canadian market.
- Step 1: Confirm Veterinary Health Product Regulatory Eligibility
- Step 2: Establish Legal Accountability and Supply Chain Roles
- Step 3: Build a Compliant Ingredient Strategy Under the List of Permitted Substances
- Step 4: Develop VHP-Compliant Claims and Evidence Support
- Step 5: Align the Product Label With VHP Regulatory Requirements
- Step 6: Complete and Validate the VHP Notification Form
- Step 7: Manage Regulatory Timelines, Fees, and Small Business Mitigation
- Step 8: Maintain Post-Notification Compliance and Product Control
- Final Remarks
- FAQs
- How do I know if my product truly qualifies as a VHP and not a veterinary drug or feed?
- Can I notify a VHP if one of my ingredients is widely used in the United States but not listed in Canada?
- What happens if Health Canada issues an information request and I do not respond in time?
- Can I sell my product while my VHP Notification is under review?
- Do I need to renew my VHP Notification every year?
Step 1: Confirm Veterinary Health Product Regulatory Eligibility
Regulatory Limits on Intended Use for Veterinary Health Products (VHPs)
To qualify as a VHP , a product must be intended solely to maintain or promote the health and wellbeing of animals, without reference to the diagnosis, treatment, prevention, or cure of disease. This includes support for normal physiological and biological functions such as digestion, joint mobility, skin and coat condition, immune function, metabolic balance, and general wellness.
If a product is represented, by its intended purpose or by implicit or explicit claims, as treating a disease or medical condition, it no longer meets the eligibility criteria for the VHP Notification Program. In such cases, the product is regulated under the veterinary drug framework, which carries significantly higher evidentiary, licensing, and compliance burdens.
This determination at the concept stage is critical because it directly influences the formulation strategy, the regulatory pathway, the level of scientific substantiation required, and the full scope of pre-market and post-market obligations.
Authorized Routes of Administration for VHPs
Only certain routes of administration are permissible under the VHP program. These permitted routes include oral, topical, otic, nasal, dental or periodontal, and in feed use. Products that are injected, inhaled, delivered into the eye, uterus, or mammary gland, applied as transdermal patches, or implanted under the skin are excluded from the VHP pathway.
Ingredient Compliance with the List of Permitted Substances
Every medicinal and non-medicinal ingredient included in a VHP t must appear on Health Canada’s List of Permitted Substances before it can be used in a VHP formulation. It is not sufficient for an ingredient to be widely used, commercially available, or accepted in other jurisdictions. Each substance must be specifically reviewed and authorized by Health Canada for use in VHPs before it can be included in a notified product.
Certain categories of substances are explicitly excluded from the VHP program by default. These include antibiotics, dewormers, most hormones, cannabis as defined under the Cannabis Act, substances listed on the Prescription Drug List, and several classes of veterinary biologics. Products containing these types of substances fall outside the scope of the VHP framework and require alternative regulatory pathways.
If a proposed ingredient does not appear on the List of Permitted Substances, the manufacturer or Notifier must submit a New Substance Application to request that the List be amended. This submission must be supported by scientific evidence demonstrating that the ingredient is safe for the intended species and conditions of use, and, where applicable, does not pose an unacceptable risk to consumers of food derived from treated animals.
Confirming Product Classification Prior to VHP Notification Submission
Many products are misclassified at the concept stage. Some are more appropriately regulated under animal feed requirements rather than the VHP framework, while others clearly fall within the veterinary drug category due to their claims, ingredient profile, or intended use. Confirming the correct classification early in development helps prevent significant rework later and ensures that the regulatory strategy, evidence planning, and labelling approach are built on a sound and defensible foundation.
Product classification is determined by a combination of factors, including proposed claims, active ingredients, route of administration, intended species, and, in certain cases, the functional role of non-medicinal ingredients. A holistic review of the entire product profile is required to determine the appropriate regulatory pathway and the most efficient route to market.
Step 2: Establish Legal Accountability and Supply Chain Roles
Notifier’s Responsibilities Under the VHP Notification Program
The Notifier is the company in whose name the VHP Notification Form is submitted and in whose name the Notification Number (NN) is issued. This is the company that Health Canada considers legally responsible for the product. The Notifier is often the brand owner or importer, but it does not need to be the physical manufacturer.
Principal Contact’s Responsibilities Under the VHP Notification Program
The Principal Contact for the Notifier is the individual who attests to the accuracy and completeness of the information submitted in the VHP Notification Form. This person is typically a director, officer, or other senior representative authorized to act on behalf of the Notifier. The Principal Contact is also the designated recipient of Health Canada invoices and official regulatory correspondence related to the notified product.
Canadian Representative’s Role for Foreign Notifiers Under the VHP Notification Program
If the Notifier is located outside of Canada, a Canadian Representative must be identified on the Notification Form, as required under the Food and Drug Regulations. The Canadian Representative serves as Health Canada’s official point of contact within Canada and is responsible for responding to regulatory enquiries, safety-related requests, and post-market compliance communications on behalf of the Notifier.
While the foreign Notifier retains full regulatory responsibility for the product, the Canadian Representative supports compliance by facilitating communication with Health Canada, supplying requested information, and coordinating responses to regulatory actions related to the notified VHP. In practice, this role is often fulfilled by a Canadian affiliate of the company or by a qualified third-party regulatory consultant that supports notification and ongoing compliance activities.
Declaring Manufacturing and Handling Sites on the VHP Notification
Every site involved in the fabrication, packaging, labelling, importing, distribution, or storage of the product must be identified on the VHP Notification Form, along with the specific role performed at each location. This information allows Health Canada to understand the complete supply chain associated with the VHP and to determine which parties are responsible for quality control and regulatory compliance at each stage of the product lifecycle. Accurate establishment listing also supports post-market oversight activities such as inspections, compliance verification, and traceability in the event of a safety concern.
Step 3: Build a Compliant Ingredient Strategy Under the List of Permitted Substances
VHP Ingredient Eligibility and Conditions Under the List of Permitted Substances
Once an ingredient is confirmed to appear on the List of Permitted Substances, it must then be assessed against its specific permitted conditions of use. Many substances are authorized only for certain animal species, restricted to defined routes of administration, or limited to maximum daily doses or concentrations. These parameters must be verified before a VHP Notification is submitted.
In addition to quantitative limits, many permitted ingredients carry mandatory regulatory warnings, cautions, and contraindications. These conditions form part of the regulatory authorization for that ingredient and must be fully applied to the finished product. All applicable warnings and risk statements must be accurately reflected on the product label and in the VHP Notification Form.
Failure to correctly apply species limitations, route restrictions, dose limits, or mandatory risk statements can result in information requests, regulatory delays, or rejection of the notification during information verification. For this reason, ingredient review under the List of Permitted Substances must extend beyond simple presence on the List and include full assessment of all attached conditions of use.
Non-Medicinal VHP Ingredients Are Also Regulated
Ingredients such as carriers, preservatives, stabilizers, flavours, and coatings must also be permitted under the List of Permitted Substances. This is especially important for products intended for food producing animals, where residues could affect the safety of the human food supply.
When a New Substance Application Is Required for VHP Ingredients
If an ingredient does not appear on the List of Permitted Substances, or if the intended species, route of administration, or conditions of use do not align with what is currently permitted, a New Substance Application must be submitted to request an amendment to the list. This submission must be supported by sufficient safety and background information to demonstrate that the proposed ingredient does not pose a significant risk to the target animal and, for food-producing animals, does not present an unacceptable risk to consumers of food derived from treated animals.
Once submitted, Health Canada conducts a scientific safety review of the application and supporting data. If the evidence adequately supports the proposed inclusion or change, the List of Permitted Substances may be amended accordingly. If the data are insufficient to establish safety under the proposed conditions of use, Health Canada may decline the request or issue a request for additional information. Where further information is requested, the applicant is expected to provide more comprehensive safety and tolerability data for the intended species at the proposed dose. If, after review of the available evidence, adequate safety cannot be demonstrated, the ingredient cannot be used in a VHP formulation, and the product must be reformulated to include only ingredients that are currently permitted on the List of Permitted Substances.
In practice, a typical New Substance Application safety package may include toxicological summaries, target animal tolerance data, published scientific literature, residue or exposure considerations for food-producing species, and a rationale for the proposed route and dosage. For example, a novel botanical extract proposed for use in cattle would require safety data addressing both animal tolerance and potential transfer into meat or milk intended for human consumption.
Proprietary Blend Disclosure Requirements for VHP Products
Proprietary active blends must be fully disclosed to Health Canada within the VHP Notification Form, including the identity and quantity of each individual active ingredient, even if the product label only displays minimum levels or collective blend information. This full disclosure allows Health Canada to properly assess safety, dose, and compliance with the List of Permitted Substances.
Proprietary flavour and fragrance blends are permitted only in certain companion animal products and are not allowed in VHPs intended for food-producing animals due to potential food safety concerns. While the detailed composition of these flavour and fragrance blends does not need to appear on the product label, Health Canada retains the authority to request full disclosure if a safety concern, complaint, or compliance issue arises.
Step 4: Develop VHP-Compliant Claims and Evidence Support
Regulations for Diseases Treatment and Prevention Claims on VHPs
VHP claims must emphasize maintaining health or supporting normal physiological functions. Examples such as promoting healthy digestion, aiding joint mobility, or improving skin condition are generally acceptable when backed by credible evidence and directly linked to the active ingredients in the formulation.
Claims that suggest disease treatment, illness prevention, or curing conditions are not permitted. Such statements typically result in rejection of the VHP notification or corrective actions when used as a part of product marketing.
| Permissible VHP Claims | Non-Permissible Claims |
|---|---|
| Supports joint comfort and mobility in senior dogs | For the management of osteoarthritis in dogs |
| Supports the maintenance of normal digestive function during diet transitions | Helps regulate blood glucose levels in diabetic cats |
| Provides nutritional support for healthy skin and coat condition | Reduces inflammatory joint disease |
| Helps maintain normal immune function during periods of stress | For the prevention of ketosis in dairy cattle |
| Supports metabolic function in performance horses | Alleviates chronic gastrointestinal disorders |
| Supports normal urinary tract function | Supports urinary tract health by preventing infections |
Evidentiary Requirements for VHP Claims
Companies must hold objective and credible evidence that supports product claims at the proposed dose, route of administration, and conditions of use. This evidence is not routinely submitted with the VHP Notification Form, but it must be available and readily accessible if Health Canada requests it in response to a safety concern, compliance review, or consumer complaint.
In practice, acceptable supporting evidence may include peer-reviewed scientific literature, established monographs or pharmacopoeial references, traditional use references where applicable, well-designed analytical or observational studies, and data demonstrating that the ingredient has a documented history of safe use in the target species at the proposed dose. For combination products, the evidence should reasonably support the overall intended effect of the formulation, not just the presence of individual ingredients.
Claim Limitations for Homeopathic and Traditional Chinese Medicine VHPs
Homeopathic and Traditional Chinese Medicine (TCM) products must follow their respective healing paradigms. Claims must reflect traditional use and cannot infer or reference medical treatment.
For example, a homeopathic Arnica product for dogs may state that it is a “homeopathic preparation traditionally used to support recovery from minor strains,” but it cannot claim to treat injuries or inflammation. Similarly, a TCM joint support product may reference concepts such as Qi or Blood in its claim, but it cannot claim to treat arthritis.
Products that combine homeopathic or TCM ingredients with western nutrients such as vitamins, minerals, or glucosamine often require special regulatory review and may no longer qualify under the VHP framework.
Step 5: Align the Product Label With VHP Regulatory Requirements
Label and Notification Form Data Consistency Requirements
The information presented on the product label must be identical to the information entered into the VHP Notification Form. This includes the brand name, product purpose, species, route of administration, dosage form, active ingredient levels, non-medicinal ingredients, warnings, and directions for use.
Principal Display Panel (PDP) Content Requirements for VHPs
The principal display panel (PDP) is the primary surface of the package that is visible under customary conditions of sale and is subject to specific regulatory content requirements for VHPs. At minimum, this panel must display the statement “Veterinary Health Product / Produit de santé animale,” the brand name, and the dosage form where it is not readily apparent based on the product presentation.
For outer labels, the principal display panel must also include the net quantity expressed in appropriate units of measure. Once issued, the Notification Number (NN) must appear clearly and legibly on the label. Any mandatory safety warnings that are critical for the safe selection and use of the product must be prominently displayed on the PDP to ensure they are readily visible to the user at the time of purchase and during normal conditions of use.
Please read Veterinary Health Product (VHP) Labelling Requirements in Canada: What You Need to Know to learn more about the labelling requirements for VHPs.
Common Labelling Deficiencies Identified During VHP Review
A significant proportion of VHP notification delays are attributable to preventable labelling deficiencies identified during administrative screening or information verification. Common issues include the absence of required French text, missing declaration of the intended species or route of administration, omission of mandatory warnings and cautions linked to the List of Permitted Substances, and branding or promotional language that implies therapeutic use beyond the scope of the VHP framework. Failure to correctly apply these elements may result in information requests, resubmission requirements, or rejection of the Notification Form.
VHP Pre-Submission Labelling Review Best Practices
Based on consistent guidance from leading regulatory compliance publications, best practices across the industry include conducting a formal, documented pre-submission label review against VHP-specific requirements, using standardized internal labelling checklists aligned with the VHP Notification Program guidance, and verifying one-to-one consistency between the final label and the VHP Notification Form prior to submission. Many companies also implement parallel regulatory and quality assurance reviews of labels to ensure that claims, directions for use, warnings, and branding elements remain aligned with VHP eligibility criteria before notification is filed.
Step 6: Complete and Validate the VHP Notification Form
Regulatory Scope of Information Captured in the Notification Form
The VHP Notification Form captures all legally relevant information required to establish regulatory accountability and product eligibility under the VHP framework. This includes identification of the Notifier and Canadian Representative where applicable, establishment listings for all sites involved in fabrication, packaging, labelling, importing, distribution, and storage, product classification details, ingredient composition, intended species, route of administration, dosage form, recommended use or purpose, and complete labelling content. All sections of the form must be completed accurately, consistently, and in a manner that directly reflects the final product as it will appear on the Canadian market. Inconsistencies or omissions at this stage can compromise the validity of the notification.
Administrative Screening Prior to Regulatory Verification
Following submission, Health Canada conducts an initial administrative screening to confirm that the Notification Form is complete and that all mandatory fields have been properly completed. This stage does not assess scientific acceptability or regulatory compliance of the ingredients or claims, but rather verifies that the submission is administratively complete and eligible to proceed to a formal review. Only after successful administrative screening does the notification advance to regulatory verification, where ingredient permissibility, claims, labelling, and overall program eligibility are formally assessed. A notification is not considered officially filed for review until it has passed this administrative screening stage.
Common Causes of Notification Rejection and Mitigation Strategies
Notification rejections most commonly occur when the product does not meet VHP eligibility criteria, contains ingredients that are not permitted under the List of Permitted Substances, includes therapeutic or disease-related claims, or shows inconsistencies between the Notification Form and the product label. Rejections may also result from unresolved administrative deficiencies or failure to respond adequately to information requests within required timelines. These risks can be significantly reduced through a structured pre-submission review process, conducted either internally or by a qualified third-party regulatory consultant. Such reviews typically focus on classification confirmation, ingredient and claim verification, and one-to-one alignment between the label and the Notification Form prior to submission.
Step 7: Manage Regulatory Timelines, Fees, and Small Business Mitigation
Notification Process, Timelines, and Administrative Outcomes
Following electronic submission through Health Canada’s VHP Notification Program portal, each Notification Form undergoes a two-stage review process consisting of administrative screening and information verification. A notification is considered administratively complete only once all mandatory fields have been correctly completed, and the product meets baseline VHP eligibility criteria. The filing date is assigned at this stage and represents the official start of regulatory processing.
If administrative deficiencies are identified, Health Canada will issue a deficiency notice and provide the Notifier with 10 calendar days to correct and resubmit the Notification Form. A maximum of two administrative resubmissions is permitted at this stage. If the deficiencies are not corrected within the required timeframe or remain unresolved after the second attempt, the Notification Form is rejected as “Rejection Incomplete Form”, and a new submission is required.
Once the Notification Form is administratively complete, it enters the information verification stage, where Health Canada reviews ingredient permissibility, claims, dosing information, and brand name acceptability for compliance with the VHP framework. If deficiencies are identified at this stage, Health Canada will issue one formal information request, and the Notifier is provided 7 calendar days to submit a complete response. Failure to respond within this period, or submission of a deficient response, results in “Rejection No Response to Request” or “Rejection Deficient Response to Request”, respectively. A rejected VHP is not considered notified and cannot be legally imported or sold in Canada.
The program operates under a 30-calendar-day performance standard, measured from the filing date of an administratively complete notification. If an information request is issued, the performance clock is paused and resumes only once a complete and acceptable response is received.
Application of Cost Recovery Fees Regardless of Review Outcome
Effective April 1, 2020, all VHP notifications and amendments that generate a new Notification Number are subject to cost recovery fees under the Fees in Respect of Drugs and Medical Devices Order. The applicable fee is indexed annually to the Consumer Price Index (CPI), with updated amounts published each fall on Health Canada’s website.
Health Canada issues the invoice only after information verification has been completed, and it is sent electronically to the Principal Contact for the Notifier with payment instructions. Notification fees apply regardless of the regulatory outcome, meaning they remain payable even when a notification is rejected due to eligibility failures, non-permitted ingredients, therapeutic claims, labelling deficiencies, or failure to adequately address an information request.
If Health Canada does not meet the established 30-day performance standard, the applicable notification fee is automatically reduced by 25%. New Substance Applications are not subject to VHP notification fees, and VHPs are not subject to annual right-to-sell or licence renewal fees, which significantly reduces long-term regulatory costs.
Eligibility for Small Business Fee Reduction and One Time Fee Waiver
Under Health Canada’s cost recovery framework, a small business is defined as an entity, including affiliates, that either employs fewer than 100 employees or generates between $30,000 and $5 million CAD in annual gross revenue. Eligible small businesses may receive:
- A 50% reduction on applicable VHP notification fees
- A one-time fee waiver for their first submission or notification
To qualify, the Notifier must first obtain a Small Business Identifier Number from Health Canada and formally register as a small business prior to submission of the Notification Form. Fee relief is not applied retroactively, and Notifiers who fail to register in advance are subject to standard fees.
Regulatory Consequences of Rejection and Insufficient Information
If a Notification Form is rejected, the product is considered ineligible for sale or importation in Canada under the VHP framework. In such cases, a completely new Notification Form must be submitted, along with payment of a new cost recovery fee, where applicable. Previously paid fees are not credited or transferred to subsequent submissions.
Failure to respond adequately to information requests, submission of partial documentation, or repeated administrative deficiencies substantially increases regulatory delay, financial exposure, and enforcement risk. As a result, pre-submission regulatory review of classification, ingredients, claims, and labelling remains the most effective strategy for avoiding preventable rejections and unnecessary cost recovery losses.
Step 8: Maintain Post-Notification Compliance and Product Control
Ongoing Good Manufacturing Practice Compliance
All establishments involved in the fabrication, packaging, labelling, importation, distribution, or storage of VHPs are required to comply with Good Manufacturing Practices (GMP) as set out in Part 3 of the Natural Health Products Regulations. This includes maintaining appropriate quality systems, conducting investigations and implementing corrective and preventive actions, ensuring proper sanitation and environmental controls, and maintaining records that support batch traceability and post-market oversight. These GMP requirements apply on an ongoing basis and are enforced through risk-based compliance and inspection activities when compliance concerns arise, despite not being subject to site licensing requirements that apply to Natural Health Products (NHPs).
Mandatory Reporting of Serious Adverse Drug Reactions
Notifiers are required to monitor and maintain records of adverse reactions associated with their notified VHPs and to report any serious adverse drug reactions to Health Canada within 15 calendar days of becoming aware of the event, in accordance with the Food and Drug Regulations and the VHP Notification Program guidance. This reporting requirement plays a critical role in post-market oversight, as it allows Health Canada to detect rare or serious safety signals, assess risk, update product safety information, issue warnings or advisories when necessary, and remove products from the market if they pose an unacceptable risk. To meet this obligation, companies must have internal systems in place to capture, assess, investigate, document adverse reactions, and ensure that complete follow-up information is submitted promptly as it becomes available.
Regulatory Control of Post-Notification Product Changes
Any significant change to a notified VHP may trigger the requirement for a new Notification Form and the issuance of a new NN. Changes that typically require resubmission include alterations to the intended species, recommended use or purpose, route of administration, dosage form, active ingredient levels, or the addition or removal of medicinal ingredients. Certain administrative updates or minor formulation changes may be screened without generating a new number. Strong internal change control procedures help ensure ongoing alignment between the marketed product, the Notification Form, and applicable regulatory requirements.
Final Remarks
Veterinary Health Product notification is a defined regulatory pathway that establishes the legal foundation for selling low risk animal health products in Canada. While it is more proportionate than traditional veterinary drug licensing, it still requires precise alignment across product classification, formulation, claims, labelling, notification strategy, fees, and post market obligations. When these elements are addressed in a structured and evidence-based manner, the pathway from concept to NN becomes predictable, efficient, and commercially viable. With the right regulatory planning in place, manufacturers and importers can avoid unnecessary delays, protect their brands, and bring compliant products to the Canadian market with confidence.
How SNI Can Support Your VHP Strategy
Navigating Veterinary Health Product (VHP) notification is not just a form completion exercise. It requires alignment across formulation, claims, labelling, GMP, evidence, and cost recovery. SNI works with brand owners, importers, and contract manufacturers to turn complex regulatory expectations into a clear, staged plan from concept through to Notification Number (NN).
Our regulatory team supports:
- Product classification and VHP eligibility assessments
- Formula reviews against the List of Permitted Substances and VHP conditions of use
- Development of compliant, bilingual VHP labels and claims
- Preparation and management of VHP Notification Forms and amendments
- Strategic support with New Substance Applications where ingredients are not yet listed
- Post notification support, including GMP readiness, adverse reaction systems, and change control
If your team is planning to launch or regularize Veterinary Health Products (VHPs) in Canada, SNI can help you reduce uncertainty, avoid preventable rejections, and bring products to market in a controlled and compliant way. To discuss your VHP portfolio or an upcoming product concept, contact our regulatory team and we will help you map out the most efficient path to notification and long term compliance.
🐾 More about our services here.
💡 Compliance is easy with the right support!
📩 info@sourcenutra.com
⬇️ Send us a request for support or an introductory call
FAQs
How do I know if my product truly qualifies as a VHP and not a veterinary drug or feed?
A product qualifies as a VHP only if it is intended to maintain or promote animal health without treating, preventing, or curing disease. Classification is based on the full product profile, including claims, ingredients, route of administration, dosage form, and intended species. If any element implies disease treatment or includes excluded ingredients such as antibiotics or dewormers, the product will fall outside the VHP framework.
Can I notify a VHP if one of my ingredients is widely used in the United States but not listed in Canada?
No. Every medicinal and non-medicinal ingredient must appear on Health Canada’s List of Permitted Substances under the specific conditions of use for the intended species, route, and dose. If an ingredient is not listed, a New Substance Application must be submitted and accepted before the ingredient can be used in a notified VHP.
What happens if Health Canada issues an information request and I do not respond in time?
If an information request is issued during the information verification stage, the Notifier has one opportunity to submit a complete response within the specified timeframe. If a satisfactory response is not provided within the allotted period, the notification is rejected and the product is not considered notified. A completely new Notification Form must be submitted to re-enter the process.
Can I sell my product while my VHP Notification is under review?
No. A VHP cannot be legally imported, sold, or distributed in Canada until an NN has been issued by Health Canada. Selling during the review period is considered non-compliant and may trigger enforcement action.
Do I need to renew my VHP Notification every year?
No. VHP Notifications do not require annual renewal and are not subject to an annual right-to-sell fee. However, Notifiers remain responsible for ongoing GMP compliance, serious adverse reaction reporting, and regulatory control of post-notification product changes.
✷ The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.
